ACIES BIO is a customer oriented contract research organization dedicated to provide the state of the art biotechnology and organic synthesis services to pharmaceutical, biotech, chemical, agro and food industry. We provide full support from idea conceptualization through research to product development, process and DSP and cover all key development steps for efficient production of biosynthetic natural products, their semi-synthetic derivatives, or entirely synthetic compounds.

With our experienced team of microbiologists, molecular biologists, fermentation scientists, biochemists and synthetic chemists, innovativeness and excellent problem solving skills and milestone-based approach to projects, we successfully support our clients’ R&D teams in development of innovative products and technologies. Our scientists’ expertise comes from decades of progressive research in internationally recognized labs from industry and academia worldwide. Our experience, commitment and dedication in providing expeditious and cost-effective solutions to our client’s research problems make us a valuable resource and partner to your organization.

general B   general D

PLEASE NOTE: ACIES BIO website is currently undergoing reconstruction. During this time, some sub-pages may not display correctly. Thank you for your understanding.

Scientists at ACIES BIO made a breakthrough innovation: high-value technology that uses unique and economic bioprocess to convert acid waste whey from dairy factories into high value animal feed products (vitamin B12) and clean water in the same process. Check out Whey2Value!

More >>
ABCloneTM is fast and efficient solution for cloning of large natural and synthetic DNA fragments. We provide ABCloneTM as a stand alone service for getting quickly your long DNA fragment sub-cloned into plasmid vector of your choice.

More >>
Acies Bio received the “Jesenko Award” from Biotechnical Faculty of University of Ljubljana. The award recognizes institutions for their outstanding research work in the field of biotechnology.

European Medicines Agency (EMA) granted orphan medicinal product designation to its lead compound CAB1803 for Pantothenate-kinase-associated neurodegeneration (PKAN)

More >>
Within H2020 SME Innovation Associate project we invite a “Disease Model Development Manager” to join our team.

More >>